Financial Performance - The company's operating revenue for Q1 2024 was CNY 2,557,512,113.04, representing a decrease of 3.86% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 18,152,447.09, an increase of 234.89% year-on-year[4]. - Basic and diluted earnings per share were both CNY 0.011, reflecting a significant increase of 266.67% compared to the previous year[4]. - The net profit for Q1 2024 was CNY 32,794,050.31, a significant increase from CNY 6,546,123.55 in Q1 2023, representing a growth of approximately 400%[18]. - The total profit before tax for Q1 2024 was CNY 58,024,653.96, compared to CNY 38,795,019.53 in Q1 2023, showing an increase of approximately 49.4%[18]. - The company reported a total comprehensive income of CNY 32,832,514.11 for Q1 2024, compared to CNY 5,308,832.16 in Q1 2023, representing a growth of about 519%[18]. - Operating profit for Q1 2024 was CNY 5,103,083.88, down from CNY 18,931,965.78 in Q1 2023, reflecting a significant decline[28]. - Net profit for Q1 2024 was CNY 5,585,680.64, compared to CNY 21,339,797.92 in Q1 2023, indicating a decrease of approximately 73.8%[28]. Cash Flow - The net cash flow from operating activities reached CNY 567,082,778.87, up by 201.87% due to land compensation of CNY 410 million received[6]. - The net cash flow from operating activities for Q1 2024 was approximately 20.17 million in Q1 2023, representing a year-over-year growth of over 2200%[30]. - Total cash inflow from operating activities was 2.34 billion in the same period last year, indicating a growth of about 15%[30]. - The cash outflow from operating activities decreased to 2.32 billion, showing a reduction of approximately 4.5%[30]. - The company incurred a net cash outflow from investing activities of CNY 192,682,233.74, compared to CNY 117,139,011.38 in Q1 2023, indicating an increase in investment expenditures[21]. - Cash flow from investing activities was negative at approximately -10.11 million in Q1 2023, reflecting an increase in investment outflows[30]. - The net cash flow from financing activities was negative CNY 489,392,313.10, a decline from a positive cash flow of CNY 308,525,208.29 in the same quarter last year[21]. - The net cash flow from financing activities was negative at approximately -106.70 million in the previous year[30]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 20,875,794,824.25, a slight decrease of 0.39% from the end of the previous year[5]. - The company's total liabilities decreased to ¥14,571,980,980.68 from ¥14,686,289,888.70, indicating a reduction in financial obligations[15]. - Total current assets as of March 31, 2024, were CNY 8,724,366,818.53, a decrease from CNY 8,956,388,289.51 at the end of 2023[25]. - Total liabilities decreased to CNY 11,362,783,383.08 as of March 31, 2024, from CNY 11,596,014,561.77 at the end of 2023[25]. - Total assets as of March 31, 2024, were CNY 18,411,368,168.43, down from CNY 18,639,013,666.48 at the end of 2023[25]. - The company's total equity increased slightly to CNY 7,048,584,785.35 as of March 31, 2024, from CNY 7,042,999,104.71 at the end of 2023[26]. Shareholder Information - The top three shareholders hold a combined total of 24.08%, 19.90%, and 11.02% of shares respectively, indicating a strong concentration of ownership[8]. - The weighted average return on equity increased to 0.34%, up by 0.24 percentage points[4]. Operational Highlights - The company has implemented cost control measures, leading to a significant increase in net profit despite a decline in revenue[6]. - There were no new product launches or major acquisitions reported during this quarter[6]. - Research and development expenses increased to CNY 16,960,117.65 in Q1 2024, compared to CNY 13,324,018.64 in Q1 2023, reflecting a growth of approximately 27.5%[27]. Other Financial Metrics - The company received government subsidies amounting to CNY 7,455,958.30, which are closely related to its normal business operations[6]. - The company received CNY 23,912,679.43 in tax refunds during Q1 2024, compared to CNY 20,478,681.49 in the same period last year, reflecting an increase of approximately 11.9%[20]. - The company's cash and cash equivalents decreased to ¥869,697,786.52 from ¥988,276,107.83, indicating a reduction in liquidity[13]. - Accounts receivable increased to ¥2,252,499,234.59 from ¥1,930,902,848.78, reflecting a rise of approximately 16.7%[13]. - The company's inventory slightly decreased to ¥2,595,132,697.44 from ¥2,607,784,499.28, indicating a marginal reduction in stock levels[13]. - Long-term borrowings increased to ¥4,486,600,885.84 from ¥4,080,858,283.77, suggesting an increase in long-term financing[15]. - The company reported a decrease in short-term loans to CNY 3,710,000,000.00 as of March 31, 2024, from CNY 3,983,500,000.00 at the end of 2023[25].
华北制药(600812) - 2024 Q1 - 季度财报